NuGen Medical Devices Provides 2025 Year End Update on R&D and Strategic Progress

Executive Summary

• NuGen Medical Devices Inc. released a comprehensive 2025 operational summary covering R&D advancements, technical capacity expansion, clinical engagement growth, and commercial activities across multiple regions.
• Key product development milestones include feasibility of a Ready‑to‑Fill Nozzle, progress on next‑generation variable‑dose jet injectors, and the launch of the EZIAUTOJECTOR® private‑label device with NHS Drug Tariff approval in the UK.
• The company broadened its global footprint by adding design and MedTech talent in the Netherlands, China, France, Brazil, and Malaysia, and initiated a Medical Advisory Board to guide future product relevance.

Key Details

• R&D Milestones
• Demonstrated feasibility of Ready‑to‑Fill Nozzle for sterile, prefilled drug formats.
• Advanced next‑generation variable‑dose jet injector to reduce training requirements.
• Initiated pressure‑profile optimization to improve injection comfort and consistency.
• Progressed prototypes of patented refill system for direct cartridge storage.

• Developed an animal‑use injector slated for release under the PetJet™ brand.

• Technical & Engineering Capacity

• Expanded Netherlands design hub with new roles focused on pharma device development.

• Added two MedTech specialists in China to enhance testing, validation, and cost‑effective development.

• Clinical & Medical Engagement

• Grew clinical teams in France, Brazil, and Malaysia to support real‑world evidence generation and patient‑experience initiatives.

• Initiated formation of a Medical Advisory Board to guide product relevance and clinical alignment.

• Commercial & Market Activity

• United Kingdom: Launched EZIAUTOJECTOR® private‑label device; secured NHS Drug Tariff approval.
• Ongoing distributor engagement, clinician feedback collection, and insurance coverage discussions in Mexico, Asia, and Canada.
• Supported Sol Millennium Medical Group’s participation at Pharmapack Europe 2026, showcasing NuGen’s needle‑free technology.

Notable Quotes

• “Our progress in 2025 reflects the disciplined work of our teams across R&D, clinical development, and global market engagement,” said Liang Lin, CEO of NuGen Medical Devices Inc. “The advancements made this year strengthen our foundation and support the continued evolution of our needle‑free technology.”